These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32355639)

  • 1. Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer.
    Tafreshi NK; Morse DL; Lee MC
    World J Clin Oncol; 2020 Apr; 11(4):169-179. PubMed ID: 32355639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
    Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
    Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
    Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.
    Johnson R; Sabnis N; McConathy WJ; Lacko AG
    Pharmaceutics; 2013; 5(2):353-70. PubMed ID: 24244833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
    Shao F; Sun H; Deng CX
    Oncotarget; 2017 Sep; 8(42):73329-73344. PubMed ID: 29069872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
    Saha P; Nanda R
    Ther Adv Med Oncol; 2016 Sep; 8(5):351-9. PubMed ID: 27583027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting triple negative breast cancer stem cells using nanocarriers.
    Dasari N; Guntuku GS; Pindiprolu SKSS
    Discov Nano; 2024 Mar; 19(1):41. PubMed ID: 38453756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    Li Y; Zhan Z; Yin X; Fu S; Deng X
    Front Oncol; 2021; 11():731535. PubMed ID: 34778045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer molecular subtypes: from TNBC to QNBC.
    Hon JD; Singh B; Sahin A; Du G; Wang J; Wang VY; Deng FM; Zhang DY; Monaco ME; Lee P
    Am J Cancer Res; 2016; 6(9):1864-1872. PubMed ID: 27725895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent therapeutic trends and promising targets in triple negative breast cancer.
    Hwang SY; Park S; Kwon Y
    Pharmacol Ther; 2019 Jul; 199():30-57. PubMed ID: 30825473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancer: a brief review of its characteristics and treatment options.
    Griffiths CL; Olin JL
    J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.